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The iridocorneal endothelial (ICE) syndrome is a rare ocular disorder that includes a group of conditions characterized by structural
and proliferative abnormalities of the corneal endothelium, the anterior chamber angle, and the iris. Common clinical features
include corneal edema, secondary glaucoma, iris atrophy, and pupillary anomalies, ranging from distortion to polycoria. The main
subtypes of this syndrome are the progressive iris atrophy, the Cogan-Reese syndrome, and the Chandler syndrome. ICE syndrome
is usually diagnosed inwomen in the adult age. Clinical history and complete eye examination including tonometry and gonioscopy
are necessary to reach a diagnosis. Imaging techniques, such as in vivo confocal microscopy and ultrasound biomicroscopy, are
used to confirm the diagnosis by revealing the presence of “ICE-cells” on the corneal endothelium and the structural changes of
the anterior chamber angle. An early diagnosis is helpful to better manage the most challenging complications such as secondary
glaucoma and corneal edema. Treatment of ICE-related glaucoma often requires glaucoma filtering surgery with antifibrotic agents
and the use of glaucoma drainage implants should be considered early in the management of these patients. Visual impairment and
pain associated with corneal edema can be successfully managed with endothelial keratoplasty.
1. Introduction
Iridocorneal endothelial (ICE) syndrome is a rare disorder
(ORPHA64734 available at http://www.orpha.net/consor/cgi-
bin/OC Exp.php?lng=en&Expert=64734) characterized by
proliferative and structural abnormalities of the corneal
endothelium, progressive obstruction of the iridocorneal
angle, and iris anomalies such as atrophy and hole for-
mation [1]. The consequences of these changes are cornea
decompensation and glaucoma, which represent the most
frequent causes of visual function loss in patients with ICE
syndrome [2]. The ICE syndrome comprises a spectrum of
clinical entities: progressive essential iris atrophy, Cogan-
Reese syndrome, and Chandler syndrome [3].
In 1903 Harms extensively described a rare ocular con-
dition characterized by iris atrophy and glaucoma, known
as “progressive essential iris atrophy” [4, 5]. Five decades
later, Chandler described a rare, unilateral ocular condi-
tion characterized by iris atrophy associated with corneal
endothelial alterations, corneal edema, and glaucoma [6].
Subsequently, it was suggested that this “Chandler syndrome”
and the “progressive essential iris atrophy” are two different
forms of the same disease [6, 7]. When Cogan and Reese
described a similar condition associated with iris nodules, a
third clinical entity was identified and subsequently named
“iris nevus” or “Cogan-Reese syndrome” [8–10]. Subsequent
studies confirmed that these clinical entities show similar
history and clinical findings and share the same pathogenic
mechanisms characterized by an abnormal proliferation of
corneal endothelium and the unifying term of “iridocorneal
endothelial syndrome” was suggested by Yanoff [1, 3, 7, 9, 11].
ICE is sporadic in presentation; it is usually unilateral
and typically affects adult patients (more often women in the
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third to fifth decade) and eventually severely compromises
the visual function if not properly treated [1]. Even when
they are promptly treated, surgical interventions for these
conditions have variable success rates and themanagement of
ICE syndrome represents a challenge for ophthalmologists.
2. Etiology
The etiology of ICE syndrome is still largely unknown;
however, a series of possible triggering events has been
described and the debate on ICE syndrome’s etiology is still
ongoing after more than a century.
Inflammation in patients with the ICE syndrome was
mentioned in few early reports and more than one author
described the onset of uveitis in these patients [10, 12]. Scheie
and Yanoff reported clumps of chronic inflammatory cells
in the iris and vitreous in one eye examined histopatholog-
ically, and Shields and colleagues observed anterior chamber
inflammation in 3 cases [1, 10]. Patel and colleagues also
mentioned that an occasional macrophage was observed on
the corneal endothelium in 2 cases [13]. Similarly, Eagle Jr.
and colleagues described a mild chronic iridocyclitis in 10
out of 16 consecutive patients diagnosed with Cogan-Reese
syndrome [3].This experience is in line with the report of the
group of Alvarado, who described 16 out of 25 patients with
ICE syndrome with a red eye or a mild uveitis before disease
onset and also documented photographically the presence of
keratic precipitates in one of these patients [12].
It was the group of Alvarado that first postulated that
the endotheliopathy responsible for the development of this
syndrome could have a viral origin [12]. In fact, they noted
that the endothelial alterations observed in ICE syndrome
patients are similar to those observed in viral disorders. In
line with this hypothesis, ICE syndrome diseases are usu-
ally monolateral acquired disorders, suggesting that affected
patients had one eye primarily affected with a virus during
the postnatal age and the other eye protected by immune
surveillance established a few weeks after the first infection.
The seldom described bilateral occurrence of ICE syndrome
could be explained by the simultaneous infection of both
eyes [12]. In addition, HSV-DNAwas detected in the aqueous
humor of patients with idiopathic corneal endotheliopathy
suggesting a viral origin of these disorders. Nevertheless a
direct proof of a relationship between ICE syndrome and
herpes simplex keratitis occurring in the same eye has not
been demonstrated [12, 14]. However, the first eight years
of studies and experiments by using ultrastructural methods
and viral cultures to confirm the hypothesis of a viral origin
for the ICE syndrome was a total failure. Nevertheless, they
did not lose faith in their hypothesis and later decided to use
a new method that seemed advantageous for the detection of
viral DNA: the polymerase chain reaction (PCR).This “new”
technique finally allowed them to detect herpes simplex
virus- (HSV-) DNA in corneal tissue and aqueous humor
samples from patients with ICE syndrome [12]. Specifically,
the authors found HSV-DNA in more than 60% of the
tested samples. They also evaluated the possible presence of
different viruses’ DNA to explain the HSV-negative samples;
however, both herpes zoster and Epstein-Barr viruses were
not detected. To further prove their results, the authors also
performed PCR to detect viral DNA in samples from healthy
subjects and from patients affected by different corneal
disorders, including bullous keratopathy and keratoconus,
and all were negative. It is interesting to underline that the
authors also performed the PCR test on the unaffected eye
of a patient with ICE syndrome that was also negative [12].
Other authors have shown that Epstein-Barr virus may also
play a role in the disease development [15].
The pioneering work of Alvarado and colleagues strongly
suggests that HSV may have a relevant etiologic role in
the development of ICE syndrome. However, it may not be
the only cause or predisposing factor and a lot has yet to
be learned on the disease etiology, which remains partially
unknown today.
3. Pathogenesis
The pathogenic mechanisms behind the clinical alterations
observed in ICE syndrome have been identified in an abnor-
mal proliferation of the corneal endothelium [16–18].
Corneal endothelium is a single layer of uniform, hexag-
onal cells localized at the inner surface of the cornea into
the anterior chamber of the eye. The corneal endothelium
lays on a basement membrane, the Descemet membrane.
Corneal endothelial cells have an embryological derivation
from neural crests. In postnatal age they are postmitotic and,
in normal conditions, do not divide. In adult age, corneal
endothelial cell density is approximately 3000 cells/mm2 and
it slightly decreases with age [19]. The function of corneal
endothelium is to actively maintain corneal transparency
through the regulation of fluid, nutrients, and solute trans-
portation between aqueous humor and the cornea structures
[20].
In 1978 Campbell and colleagues proposed the “mem-
brane theory” to explain the pathogenesis of ICE syndrome.
Specifically, they hypothesized that in the ICE syndrome
corneal endothelial cells are primarily affected and show
proliferative and structural abnormalities and the ability to
migrate into the surrounding tissues [7]. This hypothesis
was supported by the evidence obtained by studies with
specular microscopy that showed morphologic changes in
size and shape of endothelial cells, resembling epithelial
cells, also at the earliest stages of all ICE syndromes [16,
17, 21–23]. Moreover, histopathologic studies of eyes with
ICE syndrome showed altered corneal endothelial cells with
morphological characteristics resembling an epithelial-like
phenotype, named “ICE-cells” in 1985 by Sherrard and
colleagues [17, 18]. The other observations supporting this
hypothesis derive from histologic studies that demonstrated
the presence of a membrane composed of endothelial-like
cells with a basement membrane obstructing the anterior
chamber angle and covering the iris [1, 24].
It was through transmission electron microscopy studies
that it was finally confirmed that the endothelial cells of
affected patients are abnormal as they develop unique char-
acteristics of epithelial cells [25]. Specifically, electron micro-
scopic examination of these cells has evidenced desmosomes,
intracytoplasmic filaments, filopodia, and microvilli [12, 13,
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25, 26]. It is worthy of note that corneal edema observed in
patients with ICE syndrome had been explained, before these
electron microscopy studies, only by a reduction in number
of endothelial cells. However, we now know that this is not
the case, as the corneal edema is rather caused by the altered
endothelial cell function caused by multiple abnormalities of
the endothelial cell barrier. In line with the hypothesis of an
abnormal endothelial function rather than a reduced number
of endothelial cells, Bourne and Brubaker have also shown
that before chronic edema develops, the endothelial barrier is
actuallymore impermeable than in healthy subjects [27].This
observation also correlates very well with the hypothesis that
the whole disease pathogenesis may be related to reparative
activities induced by the injury of endothelial cells caused by
a viral infection or by inflammation. In fact, the formation
of microvilli and filopodia is well known during the wound-
healing process in animal models of endothelial damage
as well as in humans whose endothelial cells have been
inadvertently damaged by argon or YAG laser [28]. Thus, the
presence of these endothelial abnormalities in ICE syndrome
may simply reflect the fact that the endothelium is engaged in
reparative activities. Unfortunately, however, this activation is
later followed by cell damage and loss of function, necrosis,
and a continued decrease in cell density, which may be
explained, once again, by a viral/inflammatory etiology of the
disease [29].
Immunohistochemistry studies showed the presence of
vimentin and cytokeratins (CK) in ICE-cells [18, 30, 31].
Levy et al. demonstrated that ICE-cells expressed a profile of
differentiation markers (CK5 and CK19, but not CK3, CK8,
and CK18) that resembles that of normal limbal epithelial
cells suggesting that ICE syndrome may result from ectopic
embryonic ocular surface epithelium [32]. Alternatively,
these findings are consistent with a metaplastic stimulus
resulting in a profound change in the phenotype of normal
corneal endothelial cells [31, 32].
Regardless of the etiologic trigger, the final result of all
these cellular alterations is that the abnormal endothelial cells
in ICE syndrome migrate posteriorly beyond the Schwalbe
line to obstruct the iridocorneal angle and into the anterior
chamber to cover the iris, where they form an abnormal
basement membrane that eventually contracts triggering
pupil shape anomalies, iris atrophic damage, and formation
of synechiae between adjacent structures [7].
The angle obstruction also causes an increase of intraocu-
lar pressure (IOP) and consequent development of glaucoma
in 46% to 82% of patients with ICE syndrome [2].
4. Clinical Presentation
ICE syndrome is usually diagnosed in young adults, most
often females, although few cases have been described with
early onset in children [33–35].
Patients usually present to the ophthalmologist for a
change in the shape or position of the pupil. In other cases,
patients refer impairment of visual function that ranges
from worsening of visual function in the morning due to
the corneal decompensation at early stage to blurred vision
and/or halos around lights due to glaucoma to a constant
reduction in visual acuity. Alternatively, the first diagnosis
of an ICE syndrome is made during a routine ocular exam-
ination, following the visualization of the abnormal corneal
endothelium and/or following the evaluation of the anterior
chamber angle by gonioscopy during clinical investigations
for a glaucoma suspect.
Although clinical characteristics of ICE syndrome may
aid a correct diagnosis, in some cases with severe corneal
edema diagnosis may be difficult [2, 36]. This may be due
to difficult visualization of the anterior chamber structures
when obscured by the edema.
When the corneal endothelial function is sufficient to
guarantee corneal transparency, a careful examination of the
corneal endothelium can aid towards the diagnosis of an ICE
syndrome: a high magnification slit-lamp examination can
show a fine, “hammered-silver” or “beaten-bronze” appear-
ance of the endothelium similar to that typically observed in
Fuchs dystrophy (FECD). Changes of corneal endothelium
in ICE syndrome may be visualized and further evaluated by
specular microscopy and, more recently, by in vivo corneal
confocal microscopy [17, 37]. Demonstration of the presence
of the “ICE-cells” at specular microscopy allows confirming
the diagnosis of ICE syndrome. These ICE-cells are typically
abnormal, rounded, large, and pleomorphic, with specular
reflex showing a typical “light-dark reversal” consisting in a
dark surface, with occasional central light spot, and inter-
cellular light borders [17, 21, 23]. The four morphological
appearances of these cells described by Sherrard et al. coexist
with other cell types giving rise to the four basic ICE variants:
(i) disseminated ICE, with ICE-cells scattered throughout
an endothelium that appears otherwise essentially normal;
(ii) total ICE, with ICE-cells totally replacing the normal
endothelium; (iii) subtotal ICE(+), with ICE-cells replacing a
variable portion of the endothelium and the remaining being
composed of very small cells; and (iv) subtotal ICE(−), with
ICE-cells replacing a variable portion of the endothelium and
the remaining being composed of enlarged cells [17].
In vivo confocal microscopy (IVCM) is a noninvasive,
high resolution imaging technique that represents a useful
diagnostic tool in ICE syndrome, also in patients with corneal
edema.
It allows the study of all corneal structures at cellular
level, providing in vivo images of all corneal cells layers
comparable to ex vivo histochemical techniques. In vivo
confocal microscopy in patients with ICE syndrome will
reveal the presence of “ICE-cells” as pleomorphic epithelial-
like endothelial cells with hyperreflective nuclei and cell
boarders appearing brighter than cell surfaces [38]. Different
“epithelial-like” presentations of endothelial cells have been
described at IVCM: one type of abnormal endothelium with
quite regular size and shape, a second cell typemore irregular
in size and shape, similar to the epithelial wing cells on
IVCM, and a third, highly irregular cell pattern resembling
a surface corneal epithelium. It has been hypothesized that
these different observations may be related to the stage of the
disease [21, 39, 40].
Nevertheless, although the visualization of these cells can
allow making a diagnosis, it is usually considered mandatory
to confirm the clinical diagnosis by gonioscopy: in fact,
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the anterior chamber angle abnormalities are common to
all the ICE syndrome subtypes and include broad-based
iridotrabecular synechiae that gradually progress until a
complete angle closure develops, if not properly treated.
While the visualization of these angle alterations is not
generally difficult, it must be kept inmind that themembrane
obstructing the trabecularmeshworkmay be initially difficult
to visualize by gonioscopy, and the patients’ conditionmay be
confused with a more common open-angle glaucoma.This is
especially true if corneal edema is believed to be secondary
to the intraocular pressure increase rather than to endothelial
pump function insufficiency.
The use of ultrasound biomicroscopy (UBM) may rep-
resent a useful tool for the detection of changes of the
anterior chamber angle structures in ICE syndrome, espe-
cially in the presence of corneal edema that does not allow
gonioscopy visualization [41]. In addition, combining UBM
with gonioscopy evaluation of peripheral anterior synechiae
(PAS) may allow a better characterization of the extent
(gonioscopy) and shape (UBM) of PAS in ICE syndrome.
Zhang and colleagues reported UBM analysis of 21 eyes
with ICE syndrome and observed the presence of PAS in
all patients associated with a decrease of anterior chamber
depth when compared to normal subjects. The authors
demonstrated that UBM was more effective in revealing
both PAS and iris atrophy than clinical evaluation at slit-
lampbiomicroscopy and gonioscopy alone. Four patients also
showed angle closure in the fellow eye at UBM examination.
In addition, UBM may identify specific features of the
different clinical forms of ICE syndrome [42]. Specifically,
in patients with progressive iris atrophy, UBM showed
marked iris atrophy, and PAS were less pronounced than
in patients with Cogan-Reese syndrome. UBM in Chandler
syndrome showed the presence of marked corneal edema
with Descemet’s folds while PAS were less evident. Patients
with Cogan-Reese syndrome showed more extensive, often
“arborized” PAS. The more severe extent and height of PAS
observed by UBM in progressive iris atrophy and Cogan-
Reese syndrome support the evidence of a more severe
glaucoma observed in these ICE subtypes than in Chandler’s
syndrome [1, 42].
In any event, a strict follow-up for glaucoma must always
be performed in patients with ICE syndrome, by periodical
measuring of intraocular pressure, gonioscopy, and visual
field and retina examinations [43, 44].
As previously mentioned, once an ICE syndrome diag-
nosis is made based on these common clinical features,
there are at least three different clinical subtypes of the ICE
syndrome (Table 1). Wilson and Shields described a series
of 37 patients with ICE syndrome showing essential iris
atrophy (22%), Chandler syndrome (57%), and Cogan-Reese
syndrome (22%) to characterize this condition and describe
the clinical course over 12 years [35]. Most of the clinical
differences that allowmaking a differential diagnosis between
them are based on the different level of iris involvement and
type/severity of iris abnormalities (Table 1).
Progressive iris atrophy is characterized by marked iris
atrophy and hole(s) formation, which can be of two distinct
subtypes: stretch holes, resulting from iris thinning on the
other side of the direction of pupillary distortion, andmelting
holes, in which the iris tissue vanishes without previous signs
due to tissue ischemia (Figure 1). Gonioscopy may show the
presence of PAS causing variable degrees of angle closure and
consequent intraocular pressure increase.
In Chandler syndrome, the iris alterations are minimal
and the disease is more often diagnosed at early stage
by clinicians starting from the observation of a corneal
edema. When diagnosis is late and iris anomalies are more
pronounced, areas of iris atrophy can be observed but usually
never lead to a full-thickness iris hole (Figure 2). Glaucoma
may develop due to angle obstruction and PAS.
Finally, in Cogan-Reese syndrome different degrees of iris
atrophy can be observed; however the diagnosis is usually
made following the observation of a different feature: the
presence of multiple iris nodules, usually pedunculated,
surrounded by stromal iris showing loss of crypts and a
matted appearance. Iris nodules in Cogan-Reese syndrome
may develop late in the course of the disease, they appear as
fine, yellowish nodules on the iris surface, and later in the
disease course they become brown and increase in number.
Although from all the above it may seem that the diag-
nosis of the different ICE syndrome is quite straightforward,
in clinical practice the progressive course of the disease
often leads to a challenging diagnosis with a large percentage
of cases appearing as mixed forms in the different stages
of the disease. As it will be discussed later in detail, the
clinical management including surgical approach is usually
not linked to the exact diagnosis of the clinical subtype but
to the degree of complications such as corneal edema or
glaucoma.
Finally, since bilateral cases of ICE syndrome have been
reported and subclinical changes have been also described
in the contralateral unaffected eye, a careful examination
of the fellow eye should be performed, including slit-lamp
evaluation of the anterior segment structures, gonioscopy,
tonometry, and endothelium evaluation by specular and/or
in vivo confocal microscopy [45–48].
5. Differential Diagnosis
ICE syndrome should be considered in the differential diag-
nosis for any young adult (especially women) presenting with
unilateral iris anomalies, glaucoma, and/or corneal edema
[1]. In fact, although the aspect of the ICE syndrome is
characteristic, there are different anterior segment diseases
that may mimic it and that may be complicated by the same
issues such as corneal edema and glaucoma. Among them,
corneal endothelial disorders such as posterior polymor-
phous dystrophy (PPCD) and Fuchs endothelial dystrophy
and iris disorders such as Axenfeld-Rieger syndrome, iris
melanoma or inflammatory iris nodules, and aniridia should
be considered in the differential diagnosis.
Specifically, endothelial cells in PPCD and FECD show
epithelial-like changes and express cytokeratins similarly to
ICE syndrome [49, 50]. Among them, the FECD is the easiest
to diagnose as this disease features similar (but coarser)
endothelial anomalies in both eyes and it does not show
the anterior chamber, iridocorneal angle, or iris changes
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Table 1: Clinical features of the different ICE syndrome subtypes.
Iris Pupil Cornea Anterior chamberangle
Chandler syndrome Areas of atrophy(not full-thickness holes) Corectopia
Early and marked edema, endothelial
dystrophy, and ICE-cells at confocal
microscopy
Peripheral anterior
synechiae
Progressive iris atrophy Full-thickness hole(s) Polycoria Endothelial dystrophy, ICE-cells at confocalmicroscopy, and corneal edema may occur
Peripheral anterior
synechiae
Cogan-Reese syndrome Nodules and iris atrophy Changesuncommon
Endothelial dystrophy, ICE-cells at confocal
microscopy, and corneal edema may occur
Peripheral anterior
synechiae
(a) (b)
Figure 1: Two patients with essential iris atrophy showing extensive iris atrophy and peripheral anterior synechiae (a, b) and corneal edema
(b).
(a) (b)
Figure 2:ApatientwithChandler syndrome and glaucoma in her right eye showingmoderate corneal edema (a), polycoria (b), andperipheral
anterior synechiae. She underwent trabeculectomy 7 years earlier. Visual acuity in the right eye was 0.2 decimal units.
always seen in ICE syndrome. Differential diagnosis may be
easily reached by IVCM, which will identify the presence of
the “ICE-cells” on the corneal endothelium confirming the
diagnosis of ICE syndrome [51].
Patients with PPCD, on the other hand, can have several
features that strictly resemble the ICE syndrome, making
the differential diagnosis more challenging: in fact, in PPCD
endothelial metaplasia, pupil abnormalities, iris alterations,
corneal edema, and glaucoma caused by angle closure can
be observed [49]. Usually the natural history of the disease
and a confocal microscopy evaluation can help in making the
proper diagnosis, since, instead of the typical “ICE-cells,” in
PPCD a mixed range of endothelial vesicles and bands are
observed. However, probably the most compelling difference
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with ICE syndrome is that PPCD is bilateral, and patients
also have a typical familiar history since it is an autosomal
dominant disease [52].
Another disease that may be very challenging to dis-
tinguish from an ICE syndrome is the Axenfeld-Rieger
syndrome. In fact, even the pathogenesis of this syndrome
is similar as the iris and iridocorneal angle alterations seen
in Axenfeld-Rieger syndrome are also caused by a layer of
endothelial cells. The only difference is that in Axenfeld-
Rieger syndrome they are not secondary to the migration but
rather to the presence of a primordial endothelial layer. From
a clinical point of view, therefore, the only difference between
the two syndromes is that in Axenfeld-Rieger the findings are
bilateral and congenital and are often stationary or only have
a minor progression over time. Also, at confocal microscopy
the corneal endothelium in these patients does not appear
altered [53].
Lastly, since in aniridia there are often rudimentary iris
stumps and not a complete absence of the iris, this disease
may be confused with a late stage progressive iris atrophy.
In fact, both can be complicated by glaucoma and corneal
clouding. However, in aniridia the corneal clouding is usually
caused by a pannus due to a limbal stem cell deficiency and
not by endothelial cell dysfunction. In addition, aniridia is a
bilateral congenital disease caused by a defect in the PAX6
gene; therefore, additional congenital ocular malformations
are often present, including optic nerve hypoplasia, and
patients usually have very poor vision and nystagmus [54].
Iris nodules observed in Cogan-Reese syndrome also
require differential diagnosis with other conditions show-
ing similar iris changes such as neurofibromatosis, iris
melanoma, and sarcoidosis. Von Recklinghausen’s neurofi-
bromatosis shows pigmented iris nodules which, differently
from Cogan-Reese syndrome’s nodules, are bilateral, flatter,
andmore similar to iris nevi [55].The presence of intraocular
inflammation may help differentiate iris nodules in sarcoido-
sis form that present in Cogan-Reese syndrome.
Another important differential diagnosis of iris nodules
in Cogan-Reese syndrome is the malignant melanoma of the
iris. The presence of endothelial changes and cornea edema,
PAS, and iris atrophy may correctly orient the diagnosis
toward the ICE syndrome [56].
6. Management and Treatment
TheHSVhypothesis in the pathogenesis of the ICE syndrome
suggests that antiviral treatment may be beneficial in the
management of this disease [12]. However, this has yet to
be proven and, to date, there is no medical or surgical
treatment that can definitely solve any of the ICE syndrome
subtypes, and the final therapeutic target is the prevention
and management of the visual impairing complications,
namely, corneal edema and glaucoma.
Theuse of hypertonic saline solution instilled as eye drops
may be beneficial in themorning to reduce the corneal edema
when it is more pronounced.
Topical antiglaucomatous medications are usually the
first line of treatment, since a reduction in intraocular
pressure can also improve corneal edema. Suppressants of
aqueous humor production, including topical beta block-
ers, alpha agonists, and carbonic anhydrase inhibitors, are
preferred and are usually accompanied by miotics although
their added value is considered minimal [57]. Since the role
of HSV in ICE syndromes has not been completely ruled
out, prostaglandins should be used with caution in patients
with ICE-related glaucoma as their use has been reported
to stimulate recurrence of herpes simplex [58]. High failure
rate (from 60% to 88%) of medical treatment for glaucoma
is reported in literature and when topical treatments fail or
are insufficient, surgical approaches are followed [2, 11]. In
a case series of 82 consecutive cases, 37 (45%) required one
or more trabeculectomies [59]. Filtrating surgery in ICE-
related glaucoma showed a lower success rate than in other
types of glaucoma [2, 59, 60]. Studies showed a survival rate
of trabeculectomy of about 60% after 1 year and 40% after
2 years of follow-up [59]. These percentages decrease for
reinterventions below 20% of success rate [2]. Antifibrotic
agents have been proposed to increase the success rate of
filtrating surgery in ICE syndrome. The use of postoperative
5-fluorouracile showed failure in 5 out of 9 patients that
required additional glaucoma surgery within 1 year [61].
Intraoperative use of mitomycin-C in 10 patients with ICE
syndrome and glaucoma showed a good IOP control in 8
out of 10 eyes after a mean of 14.9 months of follow-up [60].
A larger study on 26 patients with ICE-related glaucoma
showed a survival rate of trabeculectomy with antifibrotic
agents of 73% at 1 year and 44% and 29% after 3 and 5 years
[62].This study also reported that needle andmanipulation of
the bleb and trabecular flap in these patients did not increase
the success rate [62]. The failure of filtering surgery may be
due to the progressive growth of the abnormal endothelial
membrane extending over the trabecular meshwork and
the filtration site [3, 13]. By this point of view, glaucoma
drainage implants (GDIs) may overcome the regrowth of the
membrane in the filtration site, and studies on the efficacy
of GDIs in ICE-related glaucoma showed high success rate of
about 70% at 1 year, form 70% to 40% after 3 years, and of 53%
after 5 years [62, 63]. In these studies, 20%–50% of patients
required replacement or repositioning of the tube, and the
authors advise lengthening the tube allowing the possibility
of future reposition and keeping the tip of the tube far away
from cornea and iris structures [62].
Some studies reported a higher success rate of glaucoma
management and surgery in patients with Chandler syn-
drome, and the authors hypothesize that this different clinical
outcome may be due to the less aggressive proliferative
endothelial growth observed in these patients [35, 59, 62].
Regardless of the type of surgical approach, cyclodestructive
procedures such as cyclophotocoagulation are still very often
needed because intraocular pressure control is very challeng-
ing in ICE syndrome patients, who are younger than the
typical glaucoma patient and, therefore, tend to have a more
pronounced cicatrizing response that can lead to the failure
of all filtering procedures [2].
In advanced cases of corneal edema with well-controlled
IOP, corneal surgery should be considered to improve visual
function and reduce pain. Penetrating keratoplasty (PK) was
proposed in few small reports with short follow-up, with
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variable success rate from 83% to 100% [64–67]. Penetrating
keratoplasty was able in improving visual function and pain
relief in patients with ICE syndrome; it also allowed a clear
media for monitoring of optic disc and visual field changes
in patients with associated glaucoma. Long-term results from
DeBroff and Thoft reported graft failure in 83% and graft
rejection in 2 out of the 6 eyes of patients with essential iris
atrophy treated with PK. They also reported the presence
of postoperative anterior uveitis resistant to corticosteroid
treatment in all eyes [68]. Alvim and colleagues revised the
surgical outcome in 14 patients with ICE syndrome followed
up to 58 months after PK. They reported early graft failure in
50% of patients due to rejection in 6 patients and endothelial
failure in 1 patient. At the end of follow-up, clear graft was
reported in 85% of cases, with 6 patients requiring a second
PK [69].
In 2007, M. O. Price and F. W. Price Jr. reported the
successful use of Descemet stripping with endothelial ker-
atoplasty (DSEK) in 3 pseudophakic patients with ICE syn-
drome and corneal edema, introducing endothelial surgery
in the surgical treatment of ICE syndrome [70]. Endothelial
keratoplasty is a surgical procedure that selectively replaces
dysfunctional endothelium, sparing the corneal stroma and
epithelium. This surgical technique offers several advantages
for the treatment of corneal edema in ICE syndrome, when
compared with PK. In fact, endothelial keratoplasty provides
rapid visual recovery withminimal refractive changes, avoids
the use of sutures, and better maintains corneal recipient
integrity and innervation [71]. Both deep lamellar endothelial
keratoplasty (DLEK) and the Descemet stripping endothelial
keratoplasty (DSEK) have been successfully performed in
patients with ICE syndrome [70, 72, 73].TheDSEKprocedure
consists in the replacement of abnormal endothelium and
Descemet membrane, while DLEK requires an excision of
a posterior lamella of the recipient’s cornea stroma. DSEK
is simpler and less invasive and allows more rapid visual
function recovery compared to DLEK [74]. However, DLEK
may offer some advantages in eyes with ICE syndrome
characterized by iris anomalies, PAS, and flatter anterior
chamber. In a case series of 7 phakic eyes with ICE syndrome,
DLEK was successfully performed by Huang and colleagues,
who preferred DLEK because the excision of the recipient
bed allowed an easier positioning of the donor graft with less
manipulation [75]. Recently, a new endothelial keratoplasty,
the Descemet’s membrane endothelial keratoplasty (DMEK),
has been introduced to achieve better visual recovery and
to decrease immunologic rejection [76, 77]. However, the
efficacy of this surgical approach in patients with complex
anterior ocular segment disorders, such as ICE syndrome, has
not yet been demonstrated.
Obviously, since all corneal surgery procedures do not
completely remove the abnormal endothelium, they are not
able to halt the progression of PAS and glaucoma in ICE
patients [66].
Lastly, it is worthy of note that iris reconstruction with or
without the use of intraocular prosthesis has been proposed
in ICE syndrome for both cosmetic reasons and for reducing
the visual disturbances of polycoria [78].
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